【摘要】 目的探讨紫杉醇(taxol,TAX)联合卡培他滨方案(capecitabine,CAPE)治疗Ⅳ期肺腺癌的临床疗效。方法选取贵州省黔东南州人民医院2011年03月~2013年08月肿瘤科收治的90例Ⅳ期肺腺癌患者,随机分为2组。对照组45例,给予CAPE治疗;实验组45例,给予CAPE+TAX联合治疗。治疗结束后,跟踪病例并随访,对比治疗前后2组肺腺癌患者的临床疗效及不良反应。结果近期疗效评价:实验组有效率(response rate,RR)为46.67%,疾病控制率(disease control rate,DCR)为77.78%;对照组RR率为48.89%,DCR率为73.33%,2组比较差异无统计学意义;远期疗效评价:实验组无进展生存期(progression-free survival,PFS)为(6.18±3.12)个月,对照组PFS为(3.09±2.29)个月,2组比较差异有统计学意义(P<0.05);实验组总生存期(overall survival,OS)为(9.19±2.04)个月;对照组OS为(8.63±3.93)个月,2组比较差异无统计学意义。不良反应评价:在血液学改变方面,实验组白细胞计数(white blood cell count,WBC)、中性粒细胞计数(neutrophil count,NE)较对照组下降幅度显著,差异有统计学意义(P<0.05),实验组PLT与对照组相比差异无统计学意义;在非血液学改变方面,实验组脱发较对照组发生明显较多,差异有统计学意义(P<0.05),实验组恶心呕吐、手足综合症、肝损害、口腔黏膜炎等较对照组发生无明显变化,差异无统计学意义。结论 CAPE+TAX治疗Ⅳ期肺腺癌临床效果明显,能有效提高患者无进展生存期,不良反应以血液学改变为主。更多还原

【Abstract】 Objective To explore the clinical efficacy of paclitaxel(taxol,TAX)and capecitabine scheme(capecitabine,CAPE)in treatment of Ⅳperiod lung adenocarcinoma.Methods 90 patients with IV period lung adenocarcinoma from March 2011 to August 2013 were collected and randomly divided into two groups,control group(re =45) were given CAPE treatment and experimental group(n =45) were given CAPE + TAX combination therapy.After treatment,the clinical efficacy and side effects in two groups were observed and compared.Results Evaluation of recent efficacy:the efficacy(response rate,RR)of experimental group was 46.67%,the disease control rates(DCR) was 77.78%.while RR of control group was 48.89%and DCR was 73.33%,there was no statistical significance between two groups.Evaluation of long-term efficacy:progression-free survival(PFS) in experimental group was(6.18 ±3.12)months,while in control group was(3.09 ±2.29)months,the difference was statistically significant(P <0.05).Overall survival(OS) in experimental group was(9.19 ± 2.04) months,while in control group was(8.63 ± 3.93) months,there was no statistical significance between two groups.Evaluation of adverse reaction:in terms of hematology change,white blood cell count(WBC).neutrophil counts(NE)in experimental group were decreased significantly than control group,the difference were statistically significant(P <0.05),but not the PLT.In terms of the hematology change,alopecia in experimental group was more than in control group,the difference was statistically significant(P<0.05),but there were no changes in nausea and vomiting,the brotherhood of syndrome,liver damage,oral cavity mucous membrane inflammation.Conclusion CAPE and TAX has good clinical efficacy in treatment of stage Ⅳ lung adenocarcinoma.It can increase the progression-free surial,and side effects is in hematology change.更多还原